Table 3.

Changes in Bone Turnover Markers over 12 months by Randomized Group

Median (Q1, Q3)	Standard Dose* (N=30)	P°	Moderate Dose** (N=24)	P°	High Dose*** (N=27)	P°	P†
Osteocalcin, ng/mL	−2.2 (−8.0, +4.4)	0.35	−2.5 (−8.5, +2.9)	0.21	−3.7 (−13.3, +3.5)	0.14	0.84
B-CrossLaps, ng/mL	−0.07 (−0.19, +0.15)	0.74	0.00 (−0.23, +0.14)	0.98	−0.13 (−0.31, −0.02)	0.0005	0.07
P1NP, ng/mL‡	0.0 (−13.1, +12.1)	0.61	−7.4 (−18.5, +5.8)	0.24	−15.9 (−32.2, 0.0)	0.001	0.038

^*Standard dose = 18,000 IU/month;

^**Moderate dose = 60,000 IU/month;

^***High dose = 120,000 IU/month;

^°P value for changes within group;

^†P value for differences in changes among the three dosing groups;

^‡The upper limit of detection for P1NP was 300 ng/mL, and those subjects with an unmeasurable value above the upper limit were assigned a value of 300 ng/mL for the purpose of calculation of change from baseline. Bold-faced P values indicate those <0.05. Q, quartile; 25(OH)D, 25-hydroxyvitamin D; P1NP, procollagen type 1 amino-terminal propeptide